Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502Steven M. Devine, Edwin P. Alyea, Kouros Owzar et al.|Journal of Clinical Oncology|2015Cited by 163
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L. Hertz, Howard L. McLeod, Stefanie D. Krens et al.|Clinical Cancer Research|2016Cited by 57
Genomewide Meta‐Analysis Validates a Role for <i>S1PR1</i> in Microtubule Targeting Agent‐Induced Sensory Peripheral NeuropathyKatherina C. Chua, Deanna L. Kroetz, Chenling Xiong et al.|Clinical Pharmacology & Therapeutics|2020Cited by 47
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N. Patel, Howard L. McLeod, Chen Jiang et al.|Cancer|2014Cited by 35
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patientsJúlia C.F. Quintanilha, Federico Innocenti, Jin Wang et al.|British Journal of Cancer|2021Cited by 24